Table 3. Odds ratios with 95% confidence interval of patient characteristics, surgery and postoperative management variables for short-term complications using univariate logistic regression.
|
Wound breakdown
|
Wound infection
|
Lymphocele
|
Any short-term complication
|
|||||
|---|---|---|---|---|---|---|---|---|
| Variables | N | OR (95% CI) | N | OR (95% CI) | N | OR (95% CI) | N | OR (95% CI) |
| Age (years) | 160 | 1.06 (1.02–1.10)* | 161 | 1.01 (0.98–1.03) | 161 | 1.01 (0.99–1.04) | 160 | 1.03 (1.01–1.06)* |
| Diabetes | ||||||||
| Yes | 19 | 2.99 (1.07–8.14)* | 19 | 1.99 (0.74–5.32) | 19 | 0.85 (0.29–2.51) | 19 | 4.31 (1.20–5.45)* |
| No | 141 | 1.00 (Ref) | 142 | 1.00 (Ref) | 142 | 1.00 (Ref) | 141 | 1.00 (Ref) |
| Peripheral vascular disease | ||||||||
| Yes | 8 | 2.78 (0.63–12.33) | 8 | 1.54 (0.35–6.70) | 8 | 2.56 (0.61–10.69) | 8 | 1.24 (0.00–) |
| No | 152 | 1.00 (Ref) | 153 | 1.00 (Ref) | 153 | 1.00 (Ref) | 152 | 1.00 (Ref) |
| BMI (in kg m–2) | 153 | 1.04 (0.96–1.13) | 153 | 1.05 (0.98–1.13) | 153 | 0.96 (0.89–1.04) | 153 | 1.07 (1.00–1.15) |
| Continuation of antibiotics | ||||||||
| Yes | 97 | 1.98 (0.82–4.78) | 97 | 1.13 (0.56–2.29) | 97 | 0.46 (0.23–0.93)* | 96 | 0.66 (0.35–1.28) |
| No | 62 | 1.00 (Ref) | 62 | 1.00 (Ref) | 62 | 1.00 (Ref) | 62 | 1.00 (Ref) |
| Bilateral IFL | ||||||||
| Yes | 134 | 1.94 (0.54–6.92) | 134 | 0.76 (0.32–1.85) | 134 | 1.54 (0.58–4.11) | 134 | 1.15 (0.50–2.64) |
| No | 26 | 1.00 (Ref) | 27 | 1.00 (Ref) | 27 | 1.00 (Ref) | 27 | 1.00 (Ref) |
| En bloc surgery | ||||||||
| Yes | 71 | 2.59 (1.14–5.89)* | 71 | 2.61 (1.29–5.26)* | 71 | 0.42 (0.21–0.88)* | 71 | 1.27 (0.67–2.40) |
| No | 89 | 1.00 (Ref) | 90 | 1.00 (Ref) | 90 | 1.00 (Ref) | 89 | 1.00 (Ref) |
| Ligation saphenous vein | ||||||||
| Yes | 30 | 1.84 (0.72–4.68) | 30 | 0.85 (0.35–2.08) | 30 | 1.04 (0.44–2.49) | 30 | 1.53 (0.66–3.53) |
| No | 127 | 1.00 (Ref) | 127 | 1.00 (Ref) | 127 | 1.00 (Ref) | 127 | 1.00 (Ref) |
| Total nodes dissected (number) | 160 | 0.98 (0.89–1.07) | 161 | 0.97 (0.89–1.05) | 161 | 1.03 (0.95–1.11) | 161 | 1.01 (0.94–1.08) |
| Total positive nodes (number) | 160 | 0.63 (0.35–1.15) | 161 | 1.07 (0.78–1.48) | 161 | 0.97 (0.69–1.36) | 161 | 0.91 (0.67–1.23) |
| Extracapsular growth (number) | 160 | 0.67 (0.27–1.62) | 161 | 1.20 (0.84–1.73) | 161 | 0.96 (0.63–1.44) | 161 | 0.93 (0.65–1.33) |
| Duration drain in situ (days) | 148 | 0.99 (0.89–1.09) | 148 | 1.04 (0.96–1.12) | 148 | 1.02 (0.94–1.11) | 148 | 1.01 (0.93–1.08) |
| Drain production last day (10 ml) | 121 | 1.01 (0.97–1.05) | 121 | 1.04 (1.00–1.08)* | 121 | 1.05 (1.01–1.09)* | 121 | 1.11 (1.04–1.19)* |
| Total drain production (10 ml) | 145 | 1.00 (1.00–1.00) | 145 | 1.00 (1.00–1.01) | 145 | 1.00 (1.00–1.01) | 145 | 1.00 (1.00–1.01)* |
Abbreviations: N=patients with valid observation; OR=odds ratio; CI=confidence interval; IFL=inguinofemoral lymphadenectomy; (10 ml)=odds ratio assessed per 10 ml increase of lymph fluid; Ref=reference; BMI=body mass index.
*P<0.05.